dc.creator | Caballero Velázquez, Teresa | es |
dc.creator | Montero, Isabel | es |
dc.creator | Sánchez Guijo, Fermín | es |
dc.creator | Parody, Rocío | es |
dc.creator | Saldana, Raquel | es |
dc.creator | Valcarcel, David | es |
dc.creator | Carrillo Vico, Antonio | es |
dc.creator | Márquez Malaver, Francisco J. | es |
dc.creator | Pérez Simón, José Antonio | es |
dc.date.accessioned | 2024-07-18T09:48:18Z | |
dc.date.available | 2024-07-18T09:48:18Z | |
dc.date.issued | 2016-11-30 | |
dc.identifier.citation | Caballero Velázquez, T., Montero, I., Sánchez Guijo, F., Parody, R., Saldana, R., Valcarcel, D.,...,Pérez Simón, J.A. (2016). Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. Clinical Cancer Research, 22 (23), 5673-5681. https://doi.org/10.1158/1078-0432.CCR-16-0238. | |
dc.identifier.issn | 1078-0432 | es |
dc.identifier.issn | 1557-3265 | es |
dc.identifier.uri | https://hdl.handle.net/11441/161505 | |
dc.description.abstract | Purpose: We describe the results of a prospective multicenter phase I/II trial evaluating the impact of the use of vitamin D (VitD) from day −5 to +100 on the outcome of patients undergoing allogeneic transplantation (EudraCT: 2010-023279-25; ClinicalTrials.gov: NCT02600988).
Experimental Design: A total of 150 patients were included in three consecutive cohorts of 50 patients each group: control group (CG, not receive VitD); low-dose group (LdD, received 1,000 IU VitD daily); and high-dose group (HdD, 5,000 IU VitD daily). We measured levels of VitD, cytokines, and immune subpopulations after transplantation.
Results: No significant differences were observed in terms of cumulative incidence of overall and grades 2–4 acute GVHD in terms of relapse, nonrelapse mortality, and overall survival. However, a significantly lower cumulative incidence of both overall and moderate plus severe chronic GVHD (cGVHD) at 1 year was observed in LdD (37.5% and 19.5%, respectively) and HdD (42.4% and 27%, respectively) as compared with CG (67.5% and 44.7%, respectively; P < 0.05). In multivariable analysis, treatment with VitD significantly decreased the risk of both overall (for LdD: HR = 0.31, P = 0.002; for HdD: HR = 0.36, P = 0.006) and moderate plus severe cGVHD (for LdD: HR = 0.22, P = 0.001; for HdD: HR = 0.33, P = 0.01). VitD modified the immune response, decreasing the number of B cells and naïve CD8 T cells, with a lower expression of CD40L.
Conclusions: This is the first prospective trial that analyzes the effect of VitD postransplant. We observed a significantly lower incidence of cGVHD among patients receiving VitD. Interestingly, VitD modified the immune response after allo-SCT. Clin Cancer Res; 22(23); 5673–81. ©2016 AACR. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 p. | es |
dc.language.iso | eng | es |
dc.publisher | American Association for Cancer Research | es |
dc.relation.ispartof | Clinical Cancer Research, 22 (23), 5673-5681. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | RD12/0043/0012 | es |
dc.relation.projectID | CM10/00161 | es |
dc.relation.projectID | EC10-304 | es |
dc.relation.projectID | RD12/0036/0052 | es |
dc.date.embargoEndDate | 2017-11-30 | |
dc.relation.publisherversion | https://aacrjournals.org/clincancerres/article/22/23/5673/122881/Immunomodulatory-Effect-of-Vitamin-D-after | es |
dc.identifier.doi | 10.1158/1078-0432.CCR-16-0238 | es |
dc.journaltitle | Clinical Cancer Research | es |
dc.publication.volumen | 22 | es |
dc.publication.issue | 23 | es |
dc.publication.initialPage | 5673 | es |
dc.publication.endPage | 5681 | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | Ministerio de Sanidad. España | es |
dc.contributor.funder | RTICC | es |